Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ANTI-VON willebrand factor nanobody, caplacizumab
(Cablivi, CABLIVI)		----1件: 64 💬
2ANTI-VON willebrand factor nanobody, INN = caplacizumab
(Cablivi, CABLIVI)		1件: Caplacizumab1件: Caplacizumab (Cablivi, CABLIVI) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
3Cablivi1件: Caplacizumab1件: Caplacizumab (Cablivi, CABLIVI) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
4Cablivi®----1件: 64 💬
5Caplacizumab
(Cablivi, CABLIVI)		1件: Caplacizumab1件: Caplacizumab (Cablivi, CABLIVI) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬2件: 63, 64 💬